- Start date
- 14 Sep 2024
- End date
- 14 Sep 2024
- Location
- Santander Auditorium - Hall 5
Programme
18:30
Welcome and introduction
Joyce O’Shaughnessy, Dallas, TX, USA
18:40
Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer
Elgene Lim, Darlinghurst, NSW, Australia
18:55
Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy
Cristina Saura, Barcelona, Spain
19:10
HR(+)/HER2(-) advanced breast cancer: How can biology inform us on optimising the precision therapeutic strategies in 1L and 2L post progression after endocrine+CDK4/6i?
Philippe Aftimos, Anderlecht, Belgium
19:25
A glimpse of the future: Ongoing research on novel therapeutics for advanced breast cancer patients post-progression on endocrine+CDK4/6-inhibition
Joyce O’Shaughnessy, Dallas, TX, USA
19:40
Q&A and discussion
All speakers
19:55
Concluding remarks
Cristina Saura, Barcelona, Spain
Learning objectives
- To be informed on the endocrine- and CDK4/6-related cell signalling pathways in breast cancer and obtain an expert overview on clinical and translational evidence of primary and acquired resistance mechanisms
- To acquire an overview of state of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy
- To receive insights in ongoing research on novel therapeutic options
